Collaborative Development of 2-Hydroxypropyl-β-Cyclodextrin for the Treatment of Niemann-Pick Type C1 Disease
Open accessAbstract
In 2010, the National Institutes of Health (NIH) established the Therapeutics for Rare and Neglected Diseases (TRND) program within the National Center for Advancing Translational Sciences (NCATS), which was created to stimulate drug discovery and development for rare and neglected tropical diseases through a collaborative model between the NIH, academic scientists, nonprofit organizations, and pharmaceutical and biotechnology companies. This paper describes one of the first TRND programs, the development of 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) for the treatment of Niemann-Pick disease type C1 (NPC1). NPC is a neurodegenerative, autosomal recessive rare disease caused by a mutation in either the NPC1 (about 95% of cases) or the NPC2 gene (about 5% of cases). These mutations affect the intracellular trafficking of cholesterol and other lipids, which leads to a progressive accumulation of unesterified cholesterol and glycosphingolipids in the CNS and visceral organs. Affected individuals typically exhibit ataxia, swallowing problems, seizures, and progressive impairment of motor and intellectual function in early childhood, and usually die in adolescence. There is no disease modifying therapy currently approved for NPC1 in the US. A collaborative drug development program has been established between TRND, public and private partners that has completed the pre-clinical development of HP-β-CD through IND filing for the current Phase I clinical trial that is underway. Here we discuss how this collaborative effort helped to overcome scientific, clinical and financial challenges facing the development of new drug treatments for rare and neglected diseases, and how it will incentivize the commercialization of HP-β-CD for the benefit of the NPC patient community.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cyclodextrin is a molecule known to reduce intracellular cholesterol accumulation in Niemann-Pick disease type C.
“Cyclodextrin is a molecule known to reduce intracellular cholesterol accumulation in Niemann-Pick disease type C30.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Srimaroeng, C., Cecile, J. P., Walden, R., & Pritchard, J. B. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350077 · Cited by 2,989 · see citing works
Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization
Loftsson, Þ., & Brewster, M. E. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js950534b · Cited by 2,179 · see citing works
Self-citationCyclodextrin-based pharmaceutics: past, present and future
Davis, M. E., & Brewster, M. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1576 · Cited by 2,002 · see citing works
Self-citationCyclodextrins as pharmaceutical solubilizers
Brewster, M. E., & Loftsson, Þ. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.012 · Cited by 1,892 · see citing works
Self-citationNiemann-Pick C1 Disease Gene: Homology to Mediators of Cholesterol Homeostasis
Carstea, E. D., Morris, J. A., Coleman, K. G., Loftus, S. K., Zhang, D., Cummings, C., Gu, J. Z., Rosenfeld, M. A., Pavan, W. J., Krizman, D. B., et al. (1997) · Science · doi:10.1126/science.277.5323.228 · Cited by 1,461 · see citing works
Self-citationVanier, M. T. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-16 · Cited by 1,222 · see citing works
Pharmaceutical applications of cyclodextrins: basic science and product development
Loftsson, Þ., & Brewster, M. E. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01030.x · Cited by 1,032 · see citing works
Self-citationPharmaceutical Applications of Cyclodextrins. III. Toxicological Issues and Safety Evaluation
Irie, T., & Uekama, K. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960213f · Cited by 925 · see citing works
Cellular Cholesterol Efflux Mediated by Cyclodextrins
Kilsdonk, E. P. C., Yancey, P. G., Stoudt, G. W., Bangerter, F. W., Johnson, W. J., Phillips, M. C., & Rothblat, G. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.29.17250 · Cited by 890 · see citing works
Kurkov, S. V., & Loftsson, Þ. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.06.055 · Cited by 836 · see citing works
Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery
Rajewski, R. A., & Stella, V. J. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js960075u · Cited by 823 · see citing works
Murine Model of Niemann-Pick C Disease: Mutation in a Cholesterol Homeostasis Gene
Loftus, S. K., Morris, J. A., Carstea, E. D., Gu, J. Z., Cummings, C., Brown, A., Ellison, J., Ohno, K., Rosenfeld, M. A., Tagle, D. A., et al. (1997) · Science · doi:10.1126/science.277.5323.232 · Cited by 798 · see citing works
Self-citationCyclodextrins in drug delivery
Loftsson, Þ., Jarho, P., Másson, M., & Järvinen, T. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.1.335 · Cited by 797 · see citing works
2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review
Gould, S., & Scott, R. C. (2005) · Food and Chemical Toxicology · doi:10.1016/j.fct.2005.03.007 · Cited by 746 · see citing works
Stella, V. J., & He, Q. (2008) · Toxicologic Pathology · doi:10.1177/0192623307310945 · Cited by 702 · see citing works
Kishnani, P. S., Hwu, W., Mandel, H., Nicolino, M. P., Yong, F. H., & Corzo, D. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.11.033 · Cited by 597 · see citing works
Vanier, M., & Millat, G. (2003) · Clinical Genetics · doi:10.1034/j.1399-0004.2003.00147.x · Cited by 578 · see citing works
Recommendations for the diagnosis and management of Niemann–Pick disease type C: An update
Patterson, M. C., Hendriksz, C. J., Walterfang, M., Sedel, F., Vanier, M. T., & Wijburg, F. A. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.03.012 · Cited by 473 · see citing works
Davidson, C. D., Ali, N. F., Micsenyi, M. C., Stephney, G. W., Renault, S., Dobrenis, K., Ory, D. S., Vanier, M. T., & Walkley, S. U. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006951 · Cited by 449 · see citing works
Self-citationNiemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone
Griffin, L. D., Gong, W., Verot, L., & Mellon, S. H. (2004) · Nature Medicine · doi:10.1038/nm1073 · Cited by 395 · see citing works
The adult form of Niemann-Pick disease type C
Sevin, M., Lesca, G., Baumann, N., Millat, G., Lyon‐Caen, O., Vanier, M. T., & Sedel, F. (2006) · Brain · doi:10.1093/brain/awl260 · Cited by 385 · see citing works
Porter, F. D., Scherrer, D. E., Lanier, M. H., Langmade, S. J., Molugu, V., Gale, S. E., Olzeski, D., Sidhu, R., Dietzen, D. J., Fu, R., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001417 · Cited by 340 · see citing works
Self-citationCritical role for glycosphingolipids in Niemann-Pick disease type C
Zervas, M., Somers, K. L., Thrall, M. A., & Walkley, S. U. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00396-7 · Cited by 324 · see citing works
Self-citationNatural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey
Mehta, A. B., Clarke, J. T. R., Giugliani, R., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.065904 · Cited by 310 · see citing works
Effects of Cyclodextrins on Drug Delivery Through Biological Membranes
Loftsson, Þ., Vogensen, S. B., Brewster, M. E., & Konrádsdóttir, F. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20992 · Cited by 303 · see citing works
Self-citationDysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease
Valenza, M., Rigamonti, D., Goffredo, D., Zuccato, C., Fenu, S., Jamot, L., Strand, A., Tarditi, A., Woodman, B., Racchi, M., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3355-05.2005 · Cited by 298 · see citing works
Spending on new drug development1
Adams, C., & Brantner, V. V. (2009) · Health Economics · doi:10.1002/hec.1454 · Cited by 277 · see citing works
Jiang, X., Sidhu, R., Porter, F. D., Yanjanin, N. M., Speak, A. O., Vruchte, D. T., Platt, F. M., Fujiwara, H., Scherrer, D. E., Zhang, J., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.d015735 · Cited by 270 · see citing works
Self-citationWraith, J. E., Vecchio, D., Jacklin, E., et al. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.12.006 · Cited by 208 · see citing works
Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease
Camargo, F. D., Erickson, R. P., Garver, W. S., Hossain, G. S., Carbone, P. N., Heidenreich, R. A., & Blanchard, J. D. (2001) · Life Sciences · doi:10.1016/s0024-3205(01)01384-4 · Cited by 202 · see citing works
Linear clinical progression, independent of age of onset, in Niemann–Pick disease, type C
Yanjanin, N. M., Velez, J. I., Gropman, A. L., et al. (2009) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30969 · Cited by 193 · see citing works
Self-citationLiu, B., Ramirez, C. M., Miller, A. M., Repa, J. J., Turley, S. D., & Dietschy, J. M. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m000257 · Cited by 172 · see citing works
Long-Term Miglustat Therapy in Children With Niemann-Pick Disease Type C
Patterson, M. C., Vecchio, D., Jacklin, E., et al. (2009) · Journal of Child Neurology · doi:10.1177/0883073809344222 · Cited by 166 · see citing works
Ramirez, C. M., Liu, B., Taylor, A. M., et al. (2010) · Pediatric Research · doi:10.1203/pdr.0b013e3181ee4dd2 · Cited by 159 · see citing works
Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease
Yao, J., Ho, D. J., Calingasan, N. Y., Pipalia, N. H., Lin, M. T. S., & Beal, M. F. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20121239 · Cited by 159 · see citing works
Aqul, A. A., Liu, B., Ramírez, C. M., Pieper, A. A., Estill, S. J., Burns, D. K., Liu, B., Repa, J. J., Turley, S. D., & Dietschy, J. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1317-11.2011 · Cited by 152 · see citing works
Niemann-Pick type C: A disorder of cellular cholesterol trafficking
Ory, D. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00158-x · Cited by 142 · see citing works
Self-citationEffects of cyclodextrin in two patients with Niemann–Pick Type C disease
Matsuo, M., Togawa, M., Hirabaru, K., Mochinaga, S., Narita, A., Adachi, M., Egashira, M., Irie, T., & Ohno, K. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.11.005 · Cited by 139 · see citing works
Cyclodextrin Induces Calcium-Dependent Lysosomal Exocytosis
Chen, F. W., Li, C., & Ioannou, Y. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015054 · Cited by 117 · see citing works
Ward, S. E., O’Donnell, P., Fernandez, S., & Vite, C. H. (2010) · Pediatric Research · doi:10.1203/pdr.0b013e3181df4623 · Cited by 112 · see citing works
Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU
Joppi, R., Bertelè, V., & Garattini, S. K. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1423-2 · Cited by 111 · see citing works
Peake, K., & Vance, J. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.326405 · Cited by 96 · see citing works
How to Revive Breakthrough Innovation in the Pharmaceutical Industry
Munos, B. H., & Chin, W. W. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002273 · Cited by 95 · see citing works
Cluzeau, C. V. M., Watkins‐Chow, D. E., Fu, R., Borate, B. R., Yanjanin, N. M., Dail, M. K., Davidson, C. D., Walkley, S. U., Ory, D. S., Wassif, C. A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds193 · Cited by 93 · see citing works
Self-citationPontikis, C., Davidson, C. D., Walkley, S. U., Platt, F. M., & Begley, D. J. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9583-x · Cited by 83 · see citing works
Self-citationDoes orphan drug legislation really answer the needs of patients?
Haffner, M. E., Torrent-Farnell, J., & Maher, P. D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60873-9 · Cited by 79 · see citing works
Ramirez, C. M., Liu, B., Aqul, A. A., Taylor, A. M., Repa, J. J., Turley, S. D., & Dietschy, J. M. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m013789 · Cited by 76 · see citing works
Spending on New Drug DevelopmentPreprint
Adams, C., & Brantner, V. V. (2005) · SSRN Electronic Journal · doi:10.2139/ssrn.869765 · Cited by 66 · see citing works
Dass, C. R., & Jessup, W. (2000) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357001774606 · Cited by 64 · see citing works
What the Orphan Drug Act Has Done Lately for Children With Rare Diseases: A 10-Year Analysis
Thorat, C., Xu, K., Freeman, S. N., Bonnel, R. A., Joseph, F. D., Phillips, M. I., & Imoisili, M. A. (2012) · PEDIATRICS · doi:10.1542/peds.2011-1798 · Cited by 47 · see citing works
A Call for Sharing: Adapting Pharmaceutical Research to New Realities
Munos, B. H., & Chin, W. W. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000155 · Cited by 40 · see citing works
Orphan products: an emerging trend in drug approvals
Coté, T. R., Kelkar, A., Xu, K., Braun, M. M., & Phillips, M. I. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2546-c1 · Cited by 35 · see citing works
Liu, S. M., Cogny, A., Kockx, M., Dean, R. T., Gaus, K., Jessup, W., & Kritharides, L. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200464-jlr200 · Cited by 35 · see citing works
Accelerating orphan drug development
Coté, T. R., Xu, K., & Pariser, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3340 · Cited by 31 · see citing works
Kurkov, S. V., Madden, D., Carr, D. B., et al. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23329 · Cited by 29 · see citing works
Open innovation: the new face of pharmaceutical research and development
Getz, K. A., & Kaitin, K. I. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.44 · Cited by 25 · see citing works
Translational Research and the Evolving Landscape for Biomedical Innovation
Kaitin, K. I. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318268694f · Cited by 20 · see citing works
Network for Excellence in Neuroscience Clinical Trials
Love, M. N., & Fathallh-Shaykh, H. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3663 · Cited by 10 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [9]Rare Diseases and Orphan Products: Accelerating Research and Development 2011 The National Academies Press 21796826
- [65]Vol. 52 FR 19476, May 22, 1987, as amended at 57 FR 13248, Apr. 15, 1992
Cited by
Sorted by citations
APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes
Blanchard, J. W., Akay, L. A., Davila-Velderrain, J., von Maydell, D., Mathys, H., Davidson, S. M., Effenberger, A., Chen, C.-Y., Maner-Smith, K., Hajjar, I., et al. (2022) · Nature · doi:10.1038/s41586-022-05439-w · Cited by 493 · see citing works
“Cyclodextrin is a molecule that is known to reduce intra-cellular cholesterol accumulation in Niemann–Pick disease type C 30 .”
BackgroundCholesterol in brain disease: Sometimes determinant and frequently implicated
Martín, M. G., Pfrieger, F., & Dotti, C. G. (2014) · The EMBO Reports · doi:10.15252/embr.201439225 · Cited by 304 · see citing works
Disorders in the initial steps of steroid hormone synthesis
Miller, W. L. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.009 · Cited by 205 · see citing works
Calias, P. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612823666171019164220 · Cited by 44 · see citing works
- Authors
- Ottinger, E., Kao, M., Carrillo-Carrasco, N., Yanjanin, N., Shankar, R., Janssen, M., Brewster, M., Scott, I., Xu, X., Cradock, J., Terse, P., Dehdashti, S., Marugan, J., Zheng, W., Portilla, L., Hubbs, A., Pavan, W., Heiss, J., H.Vite, C., Walkley, S., Ory, D., Silber, S., Porter, F., Austin, C., & McKew, J.
- Affiliations
- National Institutes of Health (US)
- Johnson & Johnson (United States) (US)
- Yeshiva University (US)
- Corresponding author
- Ottinger, Elizabeth
- ORCID
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-01-31
- Volume
- 14
- Issue
- 3
- Pages
- 330-339
- ISSN
- 1568-0266 (ISSN-L)
- PMC
- PMC4048128
- OpenAlex
- W2146296797
- Cited by
- 121
- References
- 58
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 4 · 2023: 7 · 2022: 7 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 11 · 2017: 16 · 2016: 21 · 2015: 17 · 2014: 7
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Topics in Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR001425, ZIBTR000004)
- National Institute of Neurological Disorders and Stroke (R01NS053677, R01NS081985)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30HD071593)
- Topics
- Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Rheumatology › Glycogen Storage Diseases and Myoclonus
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- hydroxypropyl-β-cyclodextrin, Niemann-Pick disease type C1, NPC1, NPC2, cholesterol transport, glycosphingolipid accumulation, rare disease drug development
- MeSH terms
- 2-Hydroxypropyl-beta-cyclodextrin, Cooperative Behavior, Humans, National Institutes of Health (U.S.), United States, Rare Diseases, beta-Cyclodextrins, Niemann-Pick Disease, Type C, Drug Discovery, Neglected Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
